Investing Profile

Michael Gladstone

VCInvestor
Partner at Atlas Venture
Photo of Michael Gladstone, Partner at Atlas Venture

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Harvard University Network
253 CONNECTIONS
L.E.K. Consulting Network
11 CONNECTIONS
cb
$10.0M - $50.0M
$25.0M
13
CompanyStageDateRound SizeTotal Raised
Pheon Therapeutics
Series BMay 2024$120M
Series ASep 2022$68M
$190M
Co-investors: Jonathan Tobin (Brandon Capital Partners), Rogier Rooswinkel (Forbion)
Diagonal Therapeutics
Series AApr 2024$130M
$130M
Co-investors: James N. Topper (Frazier Healthcare Partners), Jernej Godec (Atlas Venture)
SAPI
UndisclosedMar 2023
$10M
Co-investors: Edward Lando (Pareto Holdings), Jon Oringer (Pareto Holdings), Nadav Ben-Chanoch (Pareto Holdings), Mark Ransford (Double Prime LLP), Will Neale (Passion Capital), Lopo Champalimaud (V3 Ventures), Robert Dighero (Passion Capital), Mik Attisani, Tom Blomfield, Oscar Pierre
Versanis Bio
Series AAug 2021$70M
$70M
Co-investors: Joe Jimenez (Aditum Bio)
Day One Biopharmaceuticals
Series BFeb 2021$130M
Series AMay 2020$60M
$370M
Co-investors: Julie Grant (Canaan Partners), Derek DiRocco (RA Capital), Dan Becker (Access Biotechnology)
Third Harmonic Bio
Series AJan 2019$50M
$50M
Co-investors: David Bonita (OrbiMed), Jason Rhodes (Atlas Venture)
Spero Therapeutics
Series BFeb 2016$30M
Series AJun 2015$30M
Series AApr 2014$3M
SeedDec 2013
$120M
Co-investors: Krishna Yeshwant (GV (Google Ventures)), Reza Halse (RA Capital), Jean-François Formela (Atlas Venture), Vikas Goyal (SR One)
Surface Oncology
Series AJan 2015$35M
$35M
Co-investors: Elliott Sigal
Partner Atlas Venture2020 - Present
Principal Atlas Venture2015 - Present
Associate Atlas Venture2012 - 2014
Senior Associate Consultant L.E.K. Consulting2009 - 2012
MLSC Fellow Eutropics Pharmaceuticals2009 - 2009
Harvard University BA Biochemical Sciences